Celldex Therapeutics(US:CLDX) Jing Ji Guan Cha Wang·2026-02-13 17:11Company Project Progress - Barzol drug Phase III clinical trial is expected to complete patient enrollment by July 2026, which is considered the most important event of the year by management. The company also plans to initiate evaluations for new indications such as food allergies and allergic rhinitis [1] - The company plans to announce Phase II clinical trial results for nodular prurigo and atopic dermatitis in 2026, which will be used to determine the dosing regimen for subsequent registration studies [1] - Updates on the bispecific project CDX622 are expected in the third quarter of 2026, with results from a subcutaneous single-dose escalation study also planned for release within the year. Based on these data, the company intends to initiate mechanism validation studies for severe asthma [1] Strategic Advancement - The company is focused on validating its bispecific platform (CDX622) and promoting Barzol as the preferred drug in the field of CSU and other diseases. For commercialization, the company plans to independently advance in the U.S. market while considering partnerships for markets outside the U.S. [2] Institutional Perspectives - On January 7, 2026, Celldex Therapeutics' stock price surged by 5.18%, with 80% of brokerage firms giving a buy recommendation. However, it is important to note that the company is still in the research and development phase, with the latest financial report showing zero revenue and a negative net profit [3]